China's top disease control officials have suggested that the country is considering mixing the available vaccines to further boost their efficacy.
Gao Fu, director of the Chinese Centre for Disease Control and Protection said that the currently available vaccines do not have very high rates of protection and added that inoculation using vaccines of different technical lines is being considered.
He further said that another option that the officials are exploring is about taking steps to optimize the vaccine process by increasing the number of doses and changing the interval between the doses of the vaccines.
China has developed 4 domestic vaccines that are being currently used for public use. While the Brazilian clinical trials reveals Sinovac's efficacy data slightly above 50%, no detailed efficacy data have been released about the 2 other vaccines developed by Sinopharm.
Biz Expresso: Vaccines to Earnings; headlines Dalal Street is reading
Tech to kickstart earnings on Dalal Street, what to expect?
Finally some inflow! Equity MF sees net inflow after 8 months
U.S. markets end at record high as economic data points to strong recovery
Largest exchange for cryptocurrencies, Coinbase gets nod from SEC for direct listing
Wall Street kickstarts April, record high close for S&P 500 tops 4000, tech stocks lead
Lodha Developer gears for third attempt at IPO, likely to open on April 7
Margin Mayhem: Global banks fear $6 billion hit as hedge fund faces losses
Govt bets on Rs 1 lakh crore from LIC IPO
Barbeque Nation opens for business; serves hot IPO on Dalal Street
SEBI to NSE: Fix problem & take responsibility, Stricter norms imposed
Dividend booster for Bajaj shareholders
Wall Street sees biggest tumble in over 3 weeks as yields surge
Crude Oil prices sink to two week low, see longest losing streak in a year
Alleged fraud at Edelweiss Asset Reconstruction Company
Morgan Stanley gets set to offer access to bitcoin funds to clients
Wall Street scales record high as Fed remains dovish
Fed : No rate hike till 2023, raises growth outlook
Anil Agarwal 's Vedanta hikes open offer to acquire Indian unit
Nazara Technologies IPO's retail rush, subscribed over 22 times